Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
After finishing at $46.39 in the prior trading day, Janux Therapeutics Inc (NASDAQ: JANX) closed at $45.21, down -2.54%. In other words, the price has decreased by -$2.54 from its previous closing price. On the day, 0.53 million shares were traded. JANX stock price reached its highest trading level at $46.72 during the session, while it also had its lowest trading level at $45.18.
Ratios:
Our goal is to gain a better understanding of JANX by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 38.80 and its Current Ratio is at 38.80. In the meantime, Its Debt-to-Equity ratio is 0.04 whereas as Long-Term Debt/Eq ratio is at 0.03.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Leerink Partners on November 22, 2024, initiated with a Outperform rating and assigned the stock a target price of $79.
On October 24, 2024, UBS started tracking the stock assigning a Buy rating and target price of $69.
On September 06, 2024, Stifel started tracking the stock assigning a Buy rating and target price of $70.Stifel initiated its Buy rating on September 06, 2024, with a $70 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Nov 25 ’24 when Campbell David Alan sold 25,000 shares for $51.60 per share. The transaction valued at 1,289,879 led to the insider holds 257,054 shares of the business.
Reardon Tighe bought 5,202 shares of JANX for $277,987 on Nov 01 ’24. On Nov 01 ’24, another insider, Lichter Jay, who serves as the FORMER DIRECTOR of the company, bought 1,139 shares for $53.31 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, JANX now has a Market Capitalization of 2434639872 and an Enterprise Value of 1738008960. For the stock, the TTM Price-to-Sale (P/S) ratio is 177.19 while its Price-to-Book (P/B) ratio in mrq is 3.61. Its current Enterprise Value per Revenue stands at 133.191 whereas that against EBITDA is -20.719.
Stock Price History:
Over the past 52 weeks, JANX has reached a high of $65.60, while it has fallen to a 52-week low of $7.79. The 50-Day Moving Average of the stock is -9.37%, while the 200-Day Moving Average is calculated to be 1.20%.
Shares Statistics:
The stock has traded on average 647.88K shares per day over the past 3-months and 669200 shares per day over the last 10 days, according to various share statistics. A total of 46.25M shares are outstanding, with a floating share count of 42.64M. Insiders hold about 18.75% of the company’s shares, while institutions hold 86.63% stake in the company. Shares short for JANX as of 1731628800 were 4185628 with a Short Ratio of 6.46, compared to 1728950400 on 4332266. Therefore, it implies a Short% of Shares Outstanding of 4185628 and a Short% of Float of 15.67.
